On Oct. 25, 2021, Moderna announced positive interim data from the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Company’s vaccine candidate against COVID-19, in children 6 to under 12 years of age.

This interim analysis showed a robust neutralizing antibody response after two doses of mRNA-1273 at the 50 ﾵg dose level with a favorable safety profile. Moderna planned to submit these data to the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other global regulators in the near term.